Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ERBB3 |
| Variant | M91I |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | ERBB3 (HER3) M91I lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). M91I has been identified in the scientific literature (PMID: 30709382, PMID: 28388586, PMID: 29338072), but has not been biochemically characterized and therefore, its effect on Erbb3 (Her3) protein function is unknown (PubMed, Jan 2026). |
| Associated Drug Resistance | |
| Category Variants Paths |
ERBB3 mutant ERBB3 M91I |
| Transcript | NM_001982.4 |
| gDNA | chr12:g.56085033G>C |
| cDNA | c.273G>C |
| Protein | p.M91I |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001005915 | chr12:g.56085033G>C | c.273G>C | p.M91I | RefSeq | GRCh38/hg38 |
| NM_001982 | chr12:g.56085033G>C | c.273G>C | p.M91I | RefSeq | GRCh38/hg38 |
| NM_001982.3 | chr12:g.56085033G>C | c.273G>C | p.M91I | RefSeq | GRCh38/hg38 |
| NM_001005915.1 | chr12:g.56085033G>C | c.273G>C | p.M91I | RefSeq | GRCh38/hg38 |
| NM_001005915.1 | chr12:g.56085033G>C | c.273G>C | p.M91I | RefSeq | GRCh38/hg38 |
| NM_001982.4 | chr12:g.56085033G>C | c.273G>C | p.M91I | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 M91I | bladder carcinoma | sensitive | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) treatment inhibited viability of a bladder carcinoma cell line harboring ERBB3 (HER3) M91I in culture (PMID: 33473169). | 33473169 |
| ERBB3 M91I | bladder carcinoma | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, a bladder carcinoma cell line harboring ERBB3 (HER3) M91I was resistant to Tykerb (lapatinib) in culture (PMID: 33473169). | 33473169 |